We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

Berenberg Bank analyst Harry Gillis maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.11% to 5,909.03 and Dow ...

The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) with a Buy recommendation. Analyst Price Forecast Suggests 14.22% ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...